Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
(WorldNews Denmark)

Company announcement - No. 55/2017 Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes First patient recruited in the second Phase 3 clinical trial of dasiglucagon Dasiglucagon is a potential first-in-class soluble glucagon analog, for delivery in a ready-to-use rescue pen to treat severe hypoglycemia Results from the Phase 3 trial expected in H2 2018 Copenhagen, December 7, 2017 - Zealand Pharma A/S (`Zealand`) announces the initiation of the second Phase 3 trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of severe hypoglycemia in patients with Type 1 Diabetes (T1DM). Dasiglucagon...